Endocrine resistance in breast cancer

被引：21
作者：
Zheng, L. H. [1 ]
Zhao, Y. H. [2 ]
Feng, H. L. [2 ]
Liu, Y. J. [1 ]
机构：
[1] Hebei Med Univ, Affiliated Hosp 4, Dept Breast Canc Ctr, Shijiazhuang, Peoples R China
[2] Hebei Med Univ, Affiliated Hosp 4, Dept Orthoped, Shijiazhuang, Peoples R China
来源：
CLIMACTERIC | 2014年 / 17卷 / 05期
关键词：
ENDOCRINE-RESISTANT; BREAST CANCER; ESTROGENS; ACQUIRED-RESISTANCE; ESTROGEN-RECEPTOR; TAMOXIFEN RESISTANCE; MAMMALIAN TARGET; CROSS-TALK; THERAPY; PATHWAY; OVEREXPRESSION; MECHANISMS; EXPRESSION;
D O I：
10.3109/13697137.2013.864268
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to estrogen receptors (ER) and can modulate their transcriptional capabilities in different ways in diverse estrogen target tissues. Unfortunately, the use of resistant therapy is associated with acquired resistance. Several molecular mechanisms have been proposed to be responsible for endocrine resistance in breast cancer, including MIR-451, FGF and FGFR, ADAM12, fibronectin and other soluble stromal factors, PELP1-KDM1, HER2, NOTCH, delta Ef1, mTOR, AKT/mTOR, Pi3K/AKT, Pi3K/AKT/mTOR, NF kappa B, LMTK3, IGF1R, cyclin E2, IRF1, Tab2, and SRC-1. Further research is needed to know more about endocrine resistance.
引用
收藏
页码：522 / 528
页数：7
相关论文
共 42 条
  • [1] Biological reprogramming in acquired resistance to endocrine therapy of breast cancer
    Aguilar, H.
    Sole, X.
    Bonifaci, N.
    Serra-Musach, J.
    Islam, A.
    Lopez-Bigas, N.
    Mendez-Pertuz, M.
    Beijersbergen, R. L.
    Lazaro, C.
    Urruticoechea, A.
    Pujana, M. A.
    [J]. ONCOGENE, 2010, 29 (45) : 6071 - 6083
  • [2] Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks
    Alers, Sebastian
    Loeffler, Antje S.
    Wesselborg, Sebastian
    Stork, Bjoern
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2012, 32 (01) : 2 - 11
  • [3] The IGF Pathway Regulates ERα through a S6K1-Dependent Mechanism in Breast Cancer Cells
    Becker, Marc A.
    Ibrahim, Yasir H.
    Cui, Xiaojiang
    Lee, Adrian V.
    Yee, Douglas
    [J]. MOLECULAR ENDOCRINOLOGY, 2011, 25 (03) : 516 - 528
  • [4] Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance
    Bergamaschi, A.
    Katzenellenbogen, B. S.
    [J]. ONCOGENE, 2012, 31 (01) : 39 - 47
  • [5] The TOR pathway: A target for cancer therapy
    Bjornsti, MA
    Houghton, PJ
    [J]. NATURE REVIEWS CANCER, 2004, 4 (05) : 335 - 348
  • [6] Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: A review of the literature
    Boswell, Kimberly A.
    Wang, Xufang
    Shah, Manasee V.
    Aapro, Matti S.
    [J]. BREAST, 2012, 21 (06) : 701 - 706
  • [7] Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
    Caldon, C. Elizabeth
    Sergio, C. Marcelo
    Kang, Jian
    Muthukaruppan, Anita
    Boersma, Marijke N.
    Stone, Andrew
    Barraclough, Jane
    Lee, Christine S.
    Black, Michael A.
    Miller, Lance D.
    Gee, Julia M.
    Nicholson, Rob I.
    Sutherland, Robert L.
    Print, Cristin G.
    Musgrove, Elizabeth A.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (07) : 1488 - 1499
  • [8] New targets for therapy in breast cancer - Mammalian target of rapamycin (mTOR) antagonists
    Carraway, H
    Hidalgo, M
    [J]. BREAST CANCER RESEARCH, 2004, 6 (05) : 219 - 224
  • [9] Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
    Cavazzoni, Andrea
    Bonelli, Mara A.
    Fumarola, Claudia
    La Monica, Silvia
    Airoud, Kinda
    Bertoni, Ramona
    Alfieri, Roberta R.
    Galetti, Maricla
    Tramonti, Stefano
    Galvani, Elena
    Harris, Adrian L.
    Martin, Lesley-Ann
    Andreis, Daniele
    Bottini, Alberto
    Generali, Daniele
    Petronini, Pier Giorgio
    [J]. CANCER LETTERS, 2012, 323 (01) : 77 - 87
  • [10] Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer
    Cortez, Valerie
    Mann, Monica
    Tekmal, Seshidhar
    Suzuki, Takayoshi
    Miyata, Naoki
    Rodriguez-Aguayo, Cristian
    Lopez-Berestein, Gabriel
    Sood, Anil K.
    Vadlamudi, Ratna K.
    [J]. BREAST CANCER RESEARCH, 2012, 14 (04):
12345